Related Experiment Video
Updated: Feb 16, 2026
14:57
Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
Published on: October 10, 2020
15.2K
SGLT2 inhibitors
I Dardi1, T Kouvatsos1, S A Jabbour1
1Division of Endocrinology, Diabetes & Metabolic Diseases, Sidney Kimmel Medical College at Thomas Jefferson University, 211 South Ninth Street, Ste 600, Philadelphia, PA 19107, USA.
Biochemical Pharmacology
|September 13, 2015
Summary
Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer a novel approach to managing type 2 diabetes by promoting glucose excretion. These agents improve glycemic control, reduce weight and blood pressure, with a low risk of hypoglycemia.
Area of Science:
- Endocrinology
- Pharmacology
- Nephrology
Background:
- Diabetes mellitus presents a significant global health and economic challenge, with many patients failing to reach glycemic targets.
- Current treatments have limitations, highlighting the need for novel therapeutic strategies.
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a new class of antidiabetic agents with a unique insulin-independent mechanism.
Purpose of the Study:
- To review the mechanism of action, efficacy, and safety of SGLT2 inhibitors in managing type 2 diabetes mellitus (T2DM).
- To evaluate the role of SGLT2 inhibitors as a therapeutic option for T2DM patients.
- To discuss the benefits beyond glycemic control offered by SGLT2 inhibitors.
Main Methods:
- Literature review of studies on SGLT2 inhibitors in T2DM.
- Analysis of clinical trial data regarding efficacy and safety profiles.
- Pharmacological review of SGLT2 transporter function and inhibition.
Main Results:
- SGLT2 inhibitors lower blood glucose by inhibiting renal glucose reabsorption, leading to urinary glucose excretion.
- These agents demonstrate efficacy in improving glycemic control, reducing body weight, and lowering blood pressure.
- SGLT2 inhibitors are generally well-tolerated, with a low risk of hypoglycemia, but are associated with an increased incidence of genitourinary infections.
Conclusions:
- SGLT2 inhibitors are a promising therapeutic option for T2DM, offering glycemic control through an insulin-independent pathway.
- Their benefits extend to weight and blood pressure reduction, making them valuable in comprehensive diabetes management.
- While generally safe, potential side effects like genitourinary infections should be considered.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
729
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
729
01:06Oral Hypoglycemic Agents: Glinides
700
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
700
01:24Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
696
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
696
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
608
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
608
01:17Oral Hypoglycemic Agents: Sulfonylureas
1.2K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.2K